

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 2

1. - 9. (Canceled)

10. (Originally Canceled)

11. - 18. (Canceled)

19. - 24. (Originally Canceled)

Please add the following new claims 25-43, as follows:

25. (New) A *Salmonella* strain which expresses F' pilus and produces filamentous bacteriophage and is capable of targeting tumors by intravenous administration.

26. (New) A *Salmonella* strain which expresses F' pilus and produces filamentous bacteriophage and is capable of targeting tumors by intravenous administration and producing phage directly within tumors.

27. (New) The *Salmonella* according to Claim 25, wherein the *Salmonella* is attenuated.

28. (New) The *Salmonella* according to Claim 26, wherein the *Salmonella* is attenuated.

29. (New) A composition comprising the *Salmonella* of claim 25.

30. (New) A composition comprising the *Salmonella* of claim 26.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 3

31. (New) The composition according to Claim 29, wherein the *Salmonella* is attenuated.

32. (New) The composition according to Claim 30, wherein the *Salmonella* is attenuated.

33. (New) The composition according to Claim 31 in which the *Salmonella* strain is attenuated by an *msbB-* mutation.

34. (New) The composition according to Claim 31 in which the *Salmonella* is attenuated by a *pur-* mutation.

35. (New) The composition according to Claim 32 in which the *Salmonella* strain is attenuated by an *msbB-* mutation.

36. (New) The composition according to Claim 32 in which the *Salmonella* is attenuated by a *pur-* mutation.

37. (New) A method for delivering filamentous bacteriophage to solid tumors by intravenous administration of attenuated tumor-targeted *Salmonella* engineered to contain a filamentous bacteriophage of interest.

38. (New) A kit comprising an attenuated, tumor-targeting *Salmonella* expressing F' pilus suitable for delivery of a filamentous bacteriophage cloning vector to tumors by intravenous administration.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 4

39. (New) A kit according to claim 38 in which the filamentous bacteriophage cloning vector possesses a eukaryotic promoter.

40. (New) The Salmonella according to claim 25, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u. (plaque forming unit)/gram and 4.6×10^{11} p.f.u./gram of phage to tumors.

41. (New) The Salmonella according to claim 26, wherein the Salmonella is capable of delivering between 2.7×10^9 gram p.f.u./gram and 4.6×10^{11} p.f.u./gram of phage to tumors.

42. (New) The Salmonella according to claim 27, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u./gram and 5.9×10^9 p.f.u./gram of phage to tumors.

43. (New) The Salmonella according to claim 28, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u./gram and 5.9×10^9 p.f.u./gram of phage to tumors.